Clinical Trial Title LUMINA
Trial Status Open to Enrollment
Start Date 05/01/2019
Location legacy-good-samaritan-medical-center
Trial Type Ophthalmology
Specific Condition Active, Non-Infectious Uveitis

This is a Phase III study to assess the efficacy and safety of DE-109 440 µg every 2 months in subjects with active, non-infectious uveitis of the posterior segment of the eye.

There is a 6-month, single-arm, open-label period after completion of the 6-month double- masked, controlled period allows the evaluation of the efficacy and safety of intravitreal injection of DE-109 440 µg every 2 months for longer duration than appropriate for a placebo or sham control.

Eligibility Criteria
Ages Eligible for Study:  18 years and older

Sexes Eligible for Study:  All


Inclusion Criteria:

Non-Infectious Active Uveitis of the Posterior Segment

Exclusion Criteria:

Females who are pregnant, nursing, or planning a pregnancy Confirmed or suspected infectious uveitis

IRB Number 10828
Principal Investigator Sirichai Pasadhika, MD
Contact Name Tammy Mayfield
Contact Phone 503-413-7945
Contact Fax 503-413-6861
Contact E-Mail